Display Settings:

Format

Send to:

Choose Destination
    Alzheimers Res Ther. 2010 Jun 25;2(3):17.

    Pro: Can biomarkers be gold standards in Alzheimer's disease?

    Source

    Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Longwood Avenue Boston, MA 02115, USA. rsperling@rics.bwh.harvard.edu.

    Abstract

    Recent advances in biomarkers for Alzheimer's disease (AD) now allow the visualization of one of the hallmark pathologies of AD in vivo, and combination biomarker profiles can now approximate the diagnostic accuracy of autopsy in patients with dementia. Biomarkers are already employed in clinical trials in prodromal AD for both subject selection and in monitoring therapeutic response. Ultimately the greatest utility of biomarkers may be in the preclinical stages of AD, to identify and track progression of the disease prior to significant cognitive impairment, at the point when disease modifying therapies are likely to be most efficacious.

    PMID:
    20587006
    [PubMed]
    PMCID: PMC2919697
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure 1

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk